Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours Β· Estimated delivery Aug 27 - Sep 1
Dysesthesia: A New Signal for Retatrutide The TRIUMPH-4 Phase 3 trial revealed an unexpected finding: dysesthesia (abnormal touch sensations where normal sensations feel unusual or painful) in 20.9% of participants on 12 mg and 8.8% on 9 mg, compared to 0.7% on placebo (BioSpace, Dec 2025)
In our clinic, focusing on the lowest possible dose for weight loss helps to mitigate these side effects
Wilcoxon rank and chi-square tests examined the severity of symptoms reported on the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Vyvanse and Prozac Prozac is an SSRI antidepressant that contains the active drug fluoxetine
As of 2026, retatrutide has not been approved by the MHRA, FDA, EMA, or any other regulatory authority for human or veterinary use
US$ 26.30
US$ 26.50
US$ 29.77
US$ 27.87
US$ 27.54
US$ 25.68
